Know Cancer

or
forgot password

Investigation of the Cylex® ImmuKnow® Assay


N/A
18 Years
N/A
Not Enrolling
Both
Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Aplastic Anemia, Chronic Myelogenous Leukemia

Thank you

Trial Information

Investigation of the Cylex® ImmuKnow® Assay


Inclusion Criteria:



Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for
any of the following disorders are eligible:

1. Acute leukemia

2. Non-Hodgkin's Lymphoma

3. Chronic lymphocytic leukemia

4. Hodgkin's disease

5. Multiple myeloma

6. Myelodysplastic Syndromes

7. Myeloproliferative Disorders

8. Aplastic Anemia

9. Chronic myelogenous leukemia

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Principal Investigator

Sherif Farag, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Indiana University Simon Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

0710-11/ IUCRO-0207

NCT ID:

NCT00569842

Start Date:

November 2007

Completion Date:

December 2012

Related Keywords:

  • Leukemia
  • Non-Hodgkin's Lymphoma
  • Chronic Lymphocytic Leukemia
  • Hodgkin's Disease
  • Multiple Myeloma
  • Myelodysplastic Syndromes
  • Myeloproliferative Disorders
  • Aplastic Anemia
  • Chronic Myelogenous Leukemia
  • Anemia
  • Anemia, Aplastic
  • Hodgkin Disease
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Myelodysplastic Syndromes
  • Preleukemia
  • Myeloproliferative Disorders

Name

Location

Indiana Universtiy Simon Cancer CenterIndianapolis, Indiana  46202